Next Generation Sequencing in Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
Conditions: official terms
Cholangiocarcinoma - Liver Neoplasms
Conditions: Keywords
intrahepatic cholangiocarcinoma, RNAseq, risk factors, asbestos
Study Type
Study Phase
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Name: exposure to different risk factors and molecular assessment
Type: Other
Overall Status
The aim of the present study is to perform a comprehensive molecular characterization of intrahepatic cholangiocarcinoma (ICC) in patients exposed to well-known or putative risk factors (such as asbestos) for this malignancy, in order to identify possible "molecular signatures" associated to such different risk factors.
Detailed Description
Exposure to distinct risk factors of the enrolled ICC patients will be assessed by modified ReNaM questionnaire. Molecular characterization of ICC tissue samples will be carried out by RNAseq. Briefly, after surgical resection tissue samples will be immediately suspended in RNAlater. RNAseq analysis will be performed on the Illumina HiScanSQ platform. Any possible mutations identified by RNAseq will be validated by Sanger sequencing. Putative identified fusion transcripts will be confirmed by RT-PCR, using specific primers pairs located on the sequences from the exons of the two putative fusion genes. Variations in gene expression will be validated by the real-time PCR. The bioinformatic analysis will be made by using CentOS5 Server. For evaluation of asbestos fibers in tumor tissues, samples embedded in paraffin will be incinerated and then analyzed in a scanning electron microscope and by EDS spectroscopy.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- patients having a confirmed diagnosis of ICC resected;

- patients who have signed the informed consent;

- patients (males or females) who are at least 18 years old.

Exclusion Criteria:

- patients who have been treated with any medical treatment (chemotherapy or experimental standard) or with radiotherapy during the last 5 years.
Policlinico S.Orsola- Malpighi, S.S.D. Oncologia Medica- Biasco
Bologna, BO, Italy
Status: Recruiting
Contact: Giovanni Brandi - +39 0516363838 -
Start Date
May 2014
Completion Date
May 2017
University of Bologna
University of Bologna
Record processing date processed this data on July 28, 2015 page